中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2010年
6期
483-485
,共3页
胰腺肿瘤%存活率分析
胰腺腫瘤%存活率分析
이선종류%존활솔분석
Pancreatic cancer%Survival analysis
目的 探讨影响70岁及以上不可切除的胰腺癌患者生存的相关因素.方法 总结57例70岁及以上的晚期胰腺癌住院患者的临床资料,分析性别、年龄、既往糖尿病史、胆道疾病史、吸烟史、化疗、放疗、美国东部肿瘤协作组(Eastern Collaborative Oncology Group,ECOG)评分、肿瘤标志物癌胚抗原(carcinoembroynic antigen,CEA)和CA199升高情况等对总生存的影响.结果 性别、行为状态、化疗、放疗与生存密切相关.男性和女性比较,中位生存期分别为(10.7±5.4)个月和(5.5±2.3)个月,P=0.000;ECOG评分0～1分和≥2分比较,中位生存期分别为(10.1±5.8)个月和(7.3±3.8)个月,P=0.040;未接受化疗组和接受化疗组比较,中位生存期分别为(7.8±5.3)个月和(11.5±5.0)个月,P=0.038;未接受放疗组和接受放疗组比较,中位生存期分别为(8.9±5.4)个月和(13.7±3.8)个月,P=0.048;差异均有统计学意义.胰腺癌总的中位生存期为8.9个月,1年生存率为28.1%.结论 70岁及以上老年人胰腺癌的预后与性别、行为状态、化疗和放疗相关.对于不可切除但行为状态好的老年胰腺癌患可以考虑化疗,部分患者甚至可以考虑联合放疗.
目的 探討影響70歲及以上不可切除的胰腺癌患者生存的相關因素.方法 總結57例70歲及以上的晚期胰腺癌住院患者的臨床資料,分析性彆、年齡、既往糖尿病史、膽道疾病史、吸煙史、化療、放療、美國東部腫瘤協作組(Eastern Collaborative Oncology Group,ECOG)評分、腫瘤標誌物癌胚抗原(carcinoembroynic antigen,CEA)和CA199升高情況等對總生存的影響.結果 性彆、行為狀態、化療、放療與生存密切相關.男性和女性比較,中位生存期分彆為(10.7±5.4)箇月和(5.5±2.3)箇月,P=0.000;ECOG評分0～1分和≥2分比較,中位生存期分彆為(10.1±5.8)箇月和(7.3±3.8)箇月,P=0.040;未接受化療組和接受化療組比較,中位生存期分彆為(7.8±5.3)箇月和(11.5±5.0)箇月,P=0.038;未接受放療組和接受放療組比較,中位生存期分彆為(8.9±5.4)箇月和(13.7±3.8)箇月,P=0.048;差異均有統計學意義.胰腺癌總的中位生存期為8.9箇月,1年生存率為28.1%.結論 70歲及以上老年人胰腺癌的預後與性彆、行為狀態、化療和放療相關.對于不可切除但行為狀態好的老年胰腺癌患可以攷慮化療,部分患者甚至可以攷慮聯閤放療.
목적 탐토영향70세급이상불가절제적이선암환자생존적상관인소.방법 총결57례70세급이상적만기이선암주원환자적림상자료,분석성별、년령、기왕당뇨병사、담도질병사、흡연사、화료、방료、미국동부종류협작조(Eastern Collaborative Oncology Group,ECOG)평분、종류표지물암배항원(carcinoembroynic antigen,CEA)화CA199승고정황등대총생존적영향.결과 성별、행위상태、화료、방료여생존밀절상관.남성화녀성비교,중위생존기분별위(10.7±5.4)개월화(5.5±2.3)개월,P=0.000;ECOG평분0～1분화≥2분비교,중위생존기분별위(10.1±5.8)개월화(7.3±3.8)개월,P=0.040;미접수화료조화접수화료조비교,중위생존기분별위(7.8±5.3)개월화(11.5±5.0)개월,P=0.038;미접수방료조화접수방료조비교,중위생존기분별위(8.9±5.4)개월화(13.7±3.8)개월,P=0.048;차이균유통계학의의.이선암총적중위생존기위8.9개월,1년생존솔위28.1%.결론 70세급이상노년인이선암적예후여성별、행위상태、화료화방료상관.대우불가절제단행위상태호적노년이선암환가이고필화료,부분환자심지가이고필연합방료.
Objective To explore the effect of related factors on survival of patients with unresectable pancreatic cancer aged 70 years and over. Methods Fifty-seven patients with unresectable locally advanced or metastatic pancreatic cancer aged 70 years and over were enrolled.Their survival time were analyzed with SPSS 13.0 by taking account of gender, age, smoking history,alcohol history, pancreatic disease history, diabetes mellitus history, Eastern Collaborative Oncology Group (ECOG) scoring, chemotherapy, radiotherapy, CEA and CA199 levels. Results Gender,ECOG scoring, chemotherapy and radiotherapy had relationship with overall survival. The median survival time was 8.9 months and one-year survival rate was 28.1%. The median survival was (10.7±5.4) months in male group and (5.5±2.3) months in female group (P=0.000). The median survival was(10.1±5.8) months in patients with ECOG 0～1 group and(7.3±3.8)months in patients with ECOG 2 group (P=0.040). The median survival was(7.76±5.27) months in nochemotherapy group and(11.5±5.0)months in chemotherapy group (P=0.038). The median survival was(8.87±5.36)months in no radiotherapy group and (13.7±3.8) months in radiotherapy group (P=0.048). Conclusions The patients who have better ECOG performance status and receive chemotherapy or radiotherapy show better survival.
